Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Description
Invion Ltd. is a clinical-stage life sciences company, which engages in the research and development of treatment for cancers, atherosclerosis, and infectious diseases. The company was founded on October 11, 2000 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.08 - 0.5
Trade Value (12mth)
AU$3,565.00
1 week
-7.41%
1 month
52.44%
YTD
-54.13%
1 year
-75%
All time high
55.25
EPS 3 yr Growth
225.90%
EBITDA Margin
-131.60%
Operating Cashflow
-$2m
Free Cash Flow Return
-14.60%
ROIC
-34.30%
Interest Coverage
N/A
Quick Ratio
2.10
Shares on Issue (Fully Dilluted)
67m
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
13 June 25 |
Loyalty Option Entitlement Offer
×
Loyalty Option Entitlement Offer |
13 June 25 |
EQR Progresses Regional Tungsten Hub Strategy
×
EQR Progresses Regional Tungsten Hub Strategy |
11 June 25 |
Notice Under Section 708A(9)(c) of the Corporations Act
×
Notice Under Section 708A(9)(c) of the Corporations Act |
11 June 25 |
Response to ASX Cleansing Notice Timing Letter
×
Response to ASX Cleansing Notice Timing Letter |
04 June 25 |
Investor Presentation - June 2025
×
Investor Presentation - June 2025 |
02 June 25 |
Change of Registered Office Address
×
Change of Registered Office Address |
29 May 25 |
Encouraging SRC Findings on Ph I/II Skin Cancer Trial
×
Encouraging SRC Findings on Ph I/II Skin Cancer Trial |
27 May 25 |
Application for quotation of securities - IVX
×
Application for quotation of securities - IVX |
27 May 25 |
Notification regarding unquoted securities - IVX
×
Notification regarding unquoted securities - IVX |
27 May 25 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
15 May 25 |
Update - Notification regarding unquoted securities - IVX
×
Update - Notification regarding unquoted securities - IVX |
14 May 25 |
Notification regarding unquoted securities - IVX
×
Notification regarding unquoted securities - IVX |
09 May 25 |
Results of Extraordinary General Meeting
×
Results of Extraordinary General Meeting |
02 May 25 |
Dosing of 1st Six Patients in Phase I/II Skin Cancer Trial
×
Dosing of 1st Six Patients in Phase I/II Skin Cancer Trial |
30 April 25 |
Appendix 4C and Quarterly Activities Report - March 2025
×
Appendix 4C and Quarterly Activities Report - March 2025 |
08 April 25 |
Notice of Extraordinary General Meeting/Proxy Form
×
Notice of Extraordinary General Meeting/Proxy Form |
01 April 25 |
Application for quotation of securities - IVX
×
Application for quotation of securities - IVX |
01 April 25 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
13 March 25 |
Application for quotation of securities - IVX
×
Application for quotation of securities - IVX |
13 March 25 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
11 March 25 |
Update - Proposed issue of securities - IVX
×
Update - Proposed issue of securities - IVX |
05 March 25 |
Share Purchase Agreement Termination and Tranche Repayment
×
Share Purchase Agreement Termination and Tranche Repayment |
05 March 25 |
Cancel - Application for quotation of securities - IVX
×
Cancel - Application for quotation of securities - IVX |
04 March 25 |
Completion Of Placement to Accelerate Clinical Programs
×
Completion Of Placement to Accelerate Clinical Programs |
04 March 25 |
Proposed issue of securities - IVX
×
Proposed issue of securities - IVX |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.